Immunoassay Detects Severe Fever with Thrombocytopenia Syndrome Virus
|
By LabMedica International staff writers Posted on 25 Apr 2016 |

Image: A scanning electron micrograph (SEM) of severe fever with thrombocytopenia syndrome virus (Photo courtesy of the Japanese National Institute of Infectious Diseases).
Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne infectious disease with a high case fatality rate, and is caused by the SFTS virus (SFTSV) and the disease is endemic to China, South Korea, and Japan.
The viral ribonucleic acid (RNA) level in sera of patients with SFTS is known to be strongly associated with outcomes and therefore virological SFTS diagnosis with high sensitivity and specificity are required in disease endemic areas.
Scientists at the Japanese National Institute of Infectious Diseases (Tokyo, Japan) and their colleagues collected 63 serum samples from 55 acute phase patients suspected of SFTS in Japan. Viral gene detection by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) and viral antibody detection by immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) and/or indirect fluorescent antibody (IFA) were conducted to diagnose SFTS. From 55 patients, 34 of these were diagnosed as having SFTSV. Serum samples obtained from 18 healthy donors were used to establish the cut-off value of the IgG ELISA. Serum samples used for IgG ELISA were inactivated under the UV light in the biosafety cabinet for one hour.
The investigators generated novel monoclonal antibodies (MAbs) against the SFTSV nucleocapsid (N) protein and developed a sandwich antigen (Ag)-capture enzyme-linked immunosorbent assay (ELISA) for the detection of N protein of SFTSV using MAb and polyclonal antibody as capture and detection antibodies, respectively. The Ag-capture ELISAs were read using an optical density at 405 nm (OD405) was measured against a reference of 490 nm using a Model 680 Microplate Reader (Bio-Rad Laboratories Inc.; Hercules, CA, USA). The Ag-capture system was capable of detecting at least 350 to 1,220 50% Tissue Culture Infective Dose (TCID50)/100 μL/well from the culture supernatants of various SFTSV strains.
All 24 serum samples (100%) containing high copy numbers of viral RNA more than 105 copies/mL) showed a positive reaction in the Ag-capture ELISA, whereas 12 out of 15 serum samples (80%) containing low copy numbers of viral RNA (less than 105 copies/mL) showed a negative reaction in the Ag-capture ELISA. Among these Ag-capture ELISA- negative 12 samples, nine (75%) were positive for IgG antibodies against SFTSV. The authors conclude that the newly developed Ag-capture ELISA is useful for SFTS diagnosis in acute phase patients with high levels of viremia. The study was published on April 5, 2016, in the journal Public Library of Science Neglected Tropical Diseases.
The viral ribonucleic acid (RNA) level in sera of patients with SFTS is known to be strongly associated with outcomes and therefore virological SFTS diagnosis with high sensitivity and specificity are required in disease endemic areas.
Scientists at the Japanese National Institute of Infectious Diseases (Tokyo, Japan) and their colleagues collected 63 serum samples from 55 acute phase patients suspected of SFTS in Japan. Viral gene detection by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) and viral antibody detection by immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) and/or indirect fluorescent antibody (IFA) were conducted to diagnose SFTS. From 55 patients, 34 of these were diagnosed as having SFTSV. Serum samples obtained from 18 healthy donors were used to establish the cut-off value of the IgG ELISA. Serum samples used for IgG ELISA were inactivated under the UV light in the biosafety cabinet for one hour.
The investigators generated novel monoclonal antibodies (MAbs) against the SFTSV nucleocapsid (N) protein and developed a sandwich antigen (Ag)-capture enzyme-linked immunosorbent assay (ELISA) for the detection of N protein of SFTSV using MAb and polyclonal antibody as capture and detection antibodies, respectively. The Ag-capture ELISAs were read using an optical density at 405 nm (OD405) was measured against a reference of 490 nm using a Model 680 Microplate Reader (Bio-Rad Laboratories Inc.; Hercules, CA, USA). The Ag-capture system was capable of detecting at least 350 to 1,220 50% Tissue Culture Infective Dose (TCID50)/100 μL/well from the culture supernatants of various SFTSV strains.
All 24 serum samples (100%) containing high copy numbers of viral RNA more than 105 copies/mL) showed a positive reaction in the Ag-capture ELISA, whereas 12 out of 15 serum samples (80%) containing low copy numbers of viral RNA (less than 105 copies/mL) showed a negative reaction in the Ag-capture ELISA. Among these Ag-capture ELISA- negative 12 samples, nine (75%) were positive for IgG antibodies against SFTSV. The authors conclude that the newly developed Ag-capture ELISA is useful for SFTS diagnosis in acute phase patients with high levels of viremia. The study was published on April 5, 2016, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
Japanese National Institute of Infectious Diseases
Bio-Rad Laboratories
Latest Microbiology News
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreMolecular Diagnostics
view channel
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read more
Plasma ctDNA Testing Predicts Breast Cancer Recurrence After Neoadjuvant Therapy
Accurate identification of breast cancer patients at risk of relapse after pre-surgery treatment is central to guiding adjuvant decisions, particularly in aggressive disease. Circulating fragments of tumor... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreMicrobiology
view channel
WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
Tuberculosis (TB) remains a leading infectious killer, with more than 3,300 deaths and 29,000 new illnesses every day. Diagnostic delays and dependence on centralized laboratory networks continue to impede... Read more
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreTechnology
view channel
Online Tool Supports Family Screening for Inherited Cancer Risk
Genetic test results in oncology often have implications for relatives who may share inherited cancer risk. Many health systems lack structured processes to help patients alert family members, limiting... Read more
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more








